Krystal Biotech

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The firm developed a proprietary gene delivery platform that enables off-the-shelf treatments for serious rare diseases with significant unmet need, initially in the areas of dermatology and respiratory diseases. Its platform consists of a patented, engineered viral vector derived from the herpes simplex virus type 1 that is optimized for local and repeat gene transfer to epithelial cells, and initially using its platform to develop treatments for rare or orphan monogenic diseases caused by the absence of or a mutation in a single gene. It is also involved in leveraging its platform to develop novel therapies to treat more prevalent conditions, and also focuses on developing treatments for use in the setting of aesthetic skin conditions. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Krystal Biotech reports robust Q3 earnings and eyes global expansion

Krystal Biotech's Q3 performance showcased positive earnings and high patient conversion rates.
Despite challenges in patient source diversity and conversion cycle, the company remains well-positioned.
Opportunities lie in global expansion, pipeline advancement, and leadership enhancements.
Overall, Krystal Biotech's strong financials and patient compliance bode well for future growth.

Krystal Biotech excels with VYJUVEK, eyes global expansion

Krystal Biotech's VYJUVEK shows strong performance and market potential
Balanced financials and strategic clinical trials position for future growth
Challenges include competitive landscape shifts and global expansion execution
Opportunities lie in market expansion, pipeline advancements, and partnerships

Krystal Biotech excels in Q1 2024, eyes global expansion

Krystal Biotech's strong performance in Q1 2024 reflects continued growth and execution.
The company's focus on compliance, pipeline advancements, and global expansion positions it well.
Challenges in conversion time and reimbursement delays require strategic mitigation.
Opportunities in European and Japanese markets, patient education, and new product data.

Krystal Biotech excels in Q2 2024, eyes global expansion

Krystal Biotech's Q2 2024 performance reflects strong revenue growth, profitability, and operational efficiency, positioning the company well for future success.
The company's focus on patient demand, compliance, and global expansion highlights its strategic priorities and growth trajectory.
While facing challenges in manufacturing expansion and clinical data readouts, Krystal Biotech has opportunities to drive revenue growth and market expansion through strategic initiatives.

Krystal Biotech excels in Q3 with VYJUVEK success and global expansion plans

Krystal Biotech's Q3 performance reflects strong revenue growth, profitability, and strategic advancements in product development and market access.
While facing challenges related to compliance, market dynamics, and competitive landscape, the company is well-positioned for international expansion and future growth.
By capitalizing on strengths in commercial strategies, pipeline progress, and revenue diversification, Krystal Biotech can navigate challenges and seize opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Krystal Biotech, Inc. engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Krystal Biotech's Q1 2024 revenue increased to $45.25 million but fell short of analyst expectations of $47.37 million. Analysts expect Q2 earnings to be $65.49 million. Vyjuvek's patient adherence rate dropped slightly to 91% in Q1 from 96% in the previous quarter. Krystal's pipeline, beyond dermatological and aesthetic pursuits, is pretty speculative and pursuing highly contested indications.

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Artivion

Micron Technology

Sarepta Therapeutics

Seagate Technology Holdings PLC

Tidewater

Vericel

None of our picks is Nvidia or Apple or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.

7 Best Stocks For Magnificent Earnings Growth Next Year. See Who's New.

Axsome Therapeutics

Halozyme Therapeutics

Moderna

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

5 Biotech Stocks to Bet On Bright Industry Prospects

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2024 financial results on Monday, August 5, 2024, prior to the open of U.S. markets.

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Krystal Biotech (KRYS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why

Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Earnings Estimates Moving Higher for Krystal Biotech (KRYS): Time to Buy?

Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.

Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why

Krystal Biotech is a promising biotech stock with strong revenue growth after the approval of its flagship product, VYJUVEK.

Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB

PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on respiratory genetic medicine candidates KB407 and KB408 at the American Thoracic Society (ATS) 2024 International Conference being held from May 17-22, 2024 in San Diego, California.

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

PITTSBURGH, May 08, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the BofA Securities 2024 Health Care Conference on May 14, 2024, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:20 pm PT and host investor meetings throughout the day.

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

Krystal Biotech, Inc. (NASDAQ:KRYS ) Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Stéphane Paquette - VP, Business Development Krish Krishnan - Chairman and CEO Suma Krishnan - President of R&D Christine Wilson - Head of U.S. Sales and Marketing Jennifer McDonough - SVP, Patient Access, Analytics and Operations Kate Romano - Chief Accounting Officer Conference Call Participants Alec Stranahan - Bank of America Tim Lugo - William Blair Ritu Baral - TD Cowen Benazir Ali - Stifel Andrea Tan - Goldman Sachs Gavin Clark-Gartner - Evercore ISI Yigal Nochomovitz - Citigroup Operator Thank you for standing by and welcome to Krystal Biotech's First Quarter 2024 Earnings Conference Call. At this time, all participants are on a listen-only mode.

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $1.76 per share a year ago.

Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates

Net product revenue of $45.3 million in 1Q and $95.9 million since August First patient dosed in inhaled KB707 study for locally advanced or metastatic tumors of the lung Received Fast Track Designations for both inhaled and intratumoral KB707 Strong balance sheet with $622.3 million in cash and investments

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

Krystal Biotech (KRYS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Krystal Biotech (KRYS) Might Surprise This Earnings Season

PITTSBURGH, May 02, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data highlighting the potential of the Company's HSV-1 based vector platform for back of the eye gene delivery at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held from May 5-9, 2024 in Seattle, Washington.

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround

• Received Fast Track Designations for both inhaled and intratumoral KB707 PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed in its Phase 1 clinical trial (KYANITE-1) evaluating inhaled KB707, a modified HSV-1 vector designed to deliver genes encoding both human interleukin-12 (IL-12) and interleukin-2 (IL-2) to the lung, for the treatment of patients with locally advanced or metastatic solid tumors of the lung. “Cytokine therapy holds significant potential for the treatment of solid tumors but its utility has been limited by a lack of safe and effective delivery options,” said David Chien, M.D.

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable

Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model Intratumoral delivery of HSV-1 encoded IL-12 and IL-2 enhanced local and systemic effector T-cell responses in cold tumor preclinical model

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why

Catalyst Pharmaceuticals

Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.

3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List

Frequency Therapeutics Inc

Mereo Biopharma Group Plc - ADR

Takeda Pharmaceutical

Wave Life Sciences

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why

Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

News for Krystal Biotech Stock (KRYS)